Evidence map›Paper›PMID 38549003›Full record

ReviewAnnals of surgical oncology2024

Prognosis of a Heterogeneous TRG Pathological Response to Neoadjuvant Chemotherapy in Patients who Undergo Resection for Colorectal Liver Metastases.

Sophie Laroche, Olivier Scatton, Frederic Charlotte, Jean-Baptiste Bachet, Chetana Lim, David Fuks, Claire Goumard

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in Annals of surgical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06934018 (Effect of Surgical Margin Width on Recurrence and Survival in Patients With Hepatic Oligometastasis of Colorectal Cancer), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06934018 narecruitingnot on this mapstarted 2025, after this paper: background citation

Effect of Surgical Margin Width on Recurrence and Survival in Patients With Hepatic Oligometastasis of Colorectal Cancer

TypeinterventionalSponsorFudan UniversityRan2025 to 2028Enrolled140ConditionsOncology, Tumor Recurrence and MetastasisArmsSurgery and procedure
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Compact Tabletop Magnetic Resonance Elastography for Mapping Soft Tissue Viscoelasticity.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Sophie LarocheHepatobiliary Surgery and Liver Transplantation Department, Pitié Salpêtrière - APHP, Paris, France. sophie.laroche@aphp.fr.ORCID http://orcid.org/0000-0002-6456-6076
Olivier ScattonHepatobiliary Surgery and Liver Transplantation Department, Pitié Salpêtrière - APHP, Paris, France.
Frederic CharlottePathology Department, Pitié Salpêtrière - APHP, Paris, France.
Jean-Baptiste BachetDepartment of Hepatogastroenterology and Digestive Oncology, Pitié Salpêtrière - APHP, Paris, France.
Chetana LimHepatobiliary Surgery and Liver Transplantation Department, Pitié Salpêtrière - APHP, Paris, France.
David FuksDepartment of Digestive, Oncologic and Metabolic Surgery, Institut Mutualiste Montsouris, Université Paris Cité, Paris, France.
Claire GoumardHepatobiliary Surgery and Liver Transplantation Department, Pitié Salpêtrière - APHP, Paris, France.
Inserm · FRSorbonne Université · FRCentre National de la Recherche Scientifique · FRUniversité Paris Cité · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOptimal management of colorectal liver metastasis (CRLM) is based on a combination of chemotherapy and surgical resection. The tumor regression grade (TRG) score is a histological scoring system to evaluate response to chemotherapy. The prognosis of a heterogeneous response in cases of multiple metastases has not been evaluated according to the TRG score. PATIENTS AND

methodsAll patients who underwent liver resection for multiple CRLM after neoadjuvant chemotherapy in two tertiary centers from January 2015 to April 2019 were retrospectively included. Oncological characteristics and outcome between TRG 1-2-3 (good response group), TRG 4-5 (poor response group) and heterogeneous TRG (good and poor TRG among different lesions within the same patient) groups were compared.

resultsAmong the 327 patients included, 134 (41.0%) had good response (TRG 1-2-3), 120 (36.7%) had poor response (TRG 4-5), and 73 (22.3%) had heterogeneous response. The type and number of cycles of chemotherapy, k-Ras mutational status, and tumor number or size did not differ between the three groups. Use of irinotecan-based and anti-VEGF neoadjuvant therapy was associated with better TRG response [irinotecan-based: hazard ratio (OR) = 1.744; p = 0.045; anti-VEGF neoadjuvant therapy: 2.054; p = 0.005). Overall survival (OS) was higher in the 1-2-3 TRG group than in the heterogeneous TRG group (2-year OS = 81.3% vs. 60.3%, respectively; p = 0.003) and the 4-5 TRG group (2-year OS = 81.3% vs. 55.0%, respectively; p = 0.012) and similar between the heterogeneous and 4-5 TRG groups.

conclusionsThe proportion of heterogeneous pathological response according to TRG is 22.3%, and the prognosis is comparable to that of poor pathological response.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsColorectal NeoplasmsHepatectomyLiver NeoplasmsNeoadjuvant TherapyAgedChemotherapy, AdjuvantFemaleFollow-Up StudiesHumansIrinotecanMaleMiddle AgedPrognosisRetrospective StudiesSurvival RateIrinotecanAnti-VEGFColorectal cancerLiver metastasisNeoadjuvant chemotherapyPathological responseSystemic therapyTRG

Identifiers

PMID38549003
OpenAlexW4393279599

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.